Search details
1.
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
N Engl J Med
; 390(15): 1359-1371, 2024 Apr 18.
Article
in English
| MEDLINE | ID: mdl-38631003
2.
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.
Oncologist
; 29(2): 142-150, 2024 Feb 02.
Article
in English
| MEDLINE | ID: mdl-37589219
3.
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
N Engl J Med
; 385(22): 2036-2046, 2021 11 25.
Article
in English
| MEDLINE | ID: mdl-34818478
4.
Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome.
N Engl J Med
; 385(22): 2059-2065, 2021 11 25.
Article
in English
| MEDLINE | ID: mdl-34818480
5.
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
N Engl J Med
; 385(8): 683-694, 2021 08 19.
Article
in English
| MEDLINE | ID: mdl-34407342
6.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
N Engl J Med
; 384(14): 1289-1300, 2021 04 08.
Article
in English
| MEDLINE | ID: mdl-33616314
7.
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
Lancet Oncol
; 24(8): 881-891, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37451291
8.
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Lancet Oncol
; 24(3): 228-238, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36858721
9.
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial.
Int J Cancer
; 153(6): 1241-1250, 2023 09 15.
Article
in English
| MEDLINE | ID: mdl-37294085
10.
Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab.
Oncologist
; 28(6): 501-509, 2023 06 02.
Article
in English
| MEDLINE | ID: mdl-36866412
11.
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
Future Oncol
; 19(40): 2631-2640, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37882432
12.
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Lancet Oncol
; 23(6): 768-780, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35489363
13.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 380(12): 1116-1127, 2019 03 21.
Article
in English
| MEDLINE | ID: mdl-30779529
14.
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lancet Oncol
; 22(7): 946-958, 2021 07.
Article
in English
| MEDLINE | ID: mdl-34143969
15.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
N Engl J Med
; 376(11): 1015-1026, 2017 03 16.
Article
in English
| MEDLINE | ID: mdl-28212060
16.
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
Lancet Oncol
; 18(2): 212-220, 2017 Feb.
Article
in English
| MEDLINE | ID: mdl-28081914
17.
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Lancet Oncol
; 18(11): 1483-1492, 2017 11.
Article
in English
| MEDLINE | ID: mdl-28967485
18.
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer.
Cancer
; 120(1): 77-85, 2014 Jan 01.
Article
in English
| MEDLINE | ID: mdl-24108668
19.
Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.
Eur J Cancer
; 196: 113434, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38008031
20.
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
Clin Cancer Res
; 30(9): 1750-1757, 2024 May 01.
Article
in English
| MEDLINE | ID: mdl-38393723